October 3, 2026 · Peptide Legal Updates
FDA’s Import Alert 66-80, published September 21, 2026, deserves attention before a peptide business orders foreign-made GLP-1 ingredients. The updated alert describes revised submission guidance, changes to its Green List and additional product codes. For purchasers, the practical question is whether the actual manufacturer and ingredient match the current regulatory record—not whether a salesperson says the supplier is “FDA compliant.”
What changed—and what did not
This is an update to an existing border-enforcement framework, not a newly announced criminal prosecution or a ban on every imported peptide. FDA launched the GLP-1 Green List approach on September 5, 2025. Its purpose is to address potentially poor-quality active pharmaceutical ingredients entering the United States.
The current alert identifies information manufacturers may provide when seeking Green List inclusion, including manufacturing-site records, lot certificates of analysis, testing methods, stability data and quality-system documentation. It also records additions concerning orforglipron and product codes. Readers should distinguish the page’s current publication date from the original launch date; neither date establishes that a particular business has been arrested, charged or convicted.
Understand what a Green List entry means
FDA’s general import-alert explanation distinguishes Green Lists from Red Lists. Listed firms and products on a Green List are exempt from detention without physical examination under that alert; unlisted ones are not. This makes checking the correct list essential.
Detention without physical examination means FDA can hold a shipment without first testing or physically examining it. An importer must overcome the appearance of the relevant violation to obtain release. This administrative process is different from a criminal case. A customs problem should not be described publicly as proof of fraud, money laundering or a conviction.
Import eligibility also does not settle every downstream question. FDA’s current GLP-1 safety and regulatory page says the border action does not create new limits on lawful compounding. It separately explains that compounded drugs are not FDA approved and that retatrutide and cagrilintide cannot be used in compounding under federal law. A supplier’s import status cannot replace analysis of the intended finished product and business model.
A practical review before the next order
As a compliance measure, assign someone to document the manufacturer’s identity, production location, ingredient, intended use and relevant list entry before committing funds. Save a dated copy of the result. Ask who actually manufactures the material when the invoice comes from a broker. Resolve inconsistent names or addresses before relying on a supplier’s assurances.
Next, have counsel and an appropriately qualified quality professional divide the review. Counsel can assess import, distribution, advertising and compounding requirements; a technical evaluator can examine testing and quality documentation. A purity percentage on a sales sheet should not end that conversation. Contracts should address access to supporting records, notice of regulatory changes and responsibility for delays or rejected shipments.
Pharmacies and compounders have the most direct purchasing exposure, but clinics, wellness centers and chiropractic practices should understand what their dispensing partners supply. RUO sellers and influencers should have their actual claims and referral arrangements reviewed before suggesting that a supplier’s regulatory status authorizes human use. These are recommended review steps, not a finding that any particular business violated the law.
Businesses considering a new supplier or responding to a detention can request a confidential compliance review before making commitments or public claims.
General information as of October 3, 2026; not legal advice. Reading this article or requesting information does not create an attorney-client relationship.